AMBRICAN-5 contains ambrisentan, a selective endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). The medication works by relaxing pulmonary blood vessels, reducing vascular resistance, and lowering strain on the right side of the heart.
Recommended for patients:
Ambrisentan has been extensively evaluated in international clinical trials, including the ARIES-1 and ARIES-2 studies. Clinical data demonstrated improved six-minute walk distance, delayed disease progression, and enhanced quality of life in patients with PAH. The drug showed effectiveness both as monotherapy and in combination treatment regimens.
The medication is indicated for the treatment of pulmonary arterial hypertension. It is used to improve physical activity tolerance, reduce disease symptoms, and slow the progression of pulmonary vascular changes. Ambrisentan blocks endothelin activity, helping prevent narrowing of pulmonary arteries and elevated pulmonary pressure.
The medication is taken orally as prescribed by a healthcare professional, usually once daily with or without food. Tablets should be swallowed whole with water. Dosage and duration of treatment depend on the patient’s condition and therapeutic response.
Side Effects
